Patterns of calcitonin gene-related peptide monoclonal antibody use in people with migraine: Results of the OVERCOME (US) study

BackgroundUnderstanding characteristics and reasons associated with using calcitonin gene-related peptide monoclonal antibodies (CGRP mAb) for migraine prevention may help clinicians individualize treatment plans and achieve better patient outcomes.MethodsWe analyzed 2019-2020 cohort data of OVERCOM...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cephalalgia Ročník 45; číslo 6; s. 3331024251341243
Hlavní autoři: Ashina, Sait, Kim, Gilwan, Muenzel, E Jolanda, Buse, Dawn C, Zagar, Anthony J, Zakharyan, Armen, Shapiro, Robert E, Nicholson, Robert A, Pearlman, Eric M, Lipton, Richard B
Médium: Journal Article
Jazyk:angličtina
Vydáno: England 01.06.2025
Témata:
Adult
Antibodies, Monoclonal - therapeutic use
Calcitonin Gene-Related Peptide - antagonists & inhibitors
Calcitonin Gene-Related Peptide - immunology
Calcitonin Gene-Related Peptide Receptor Antagonists - therapeutic use
Cohort Studies
Female
Humans
Male
Middle Aged
Migraine Disorders - drug therapy
Migraine Disorders - epidemiology
Migraine Disorders - prevention & control
United States
United States
migraine
monoclonal antibody
CGRP
OVERCOME
ISSN:1468-2982, 1468-2982
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:BackgroundUnderstanding characteristics and reasons associated with using calcitonin gene-related peptide monoclonal antibodies (CGRP mAb) for migraine prevention may help clinicians individualize treatment plans and achieve better patient outcomes.MethodsWe analyzed 2019-2020 cohort data of OVERCOME (US), a population-based survey among adults with migraine. Eligible participants were categorized based on current CGRP mAb usage ("NEVER" and "EVER" users ["Continued", "Switched" and "Discontinued"]). Machine learning techniques followed by logistic regression were used to examine, among 60 sociodemographic, clinical, migraine-related- and migraine treatment utilization characteristics, those associated with CGRP mAb use status.ResultsOf 39,113 participants, 25.6% had ever used migraine preventive medication(s) and 5.0% used CGRP mAbs (of which 46.1% Continued, 14.7% Switched and 39.3% Discontinued). Top factors associated with higher odds of CGRP mAb EVER vs. NEVER use were currently using recommended acute medication (odds ratio (OR) = 2.43; 95% confidence interval (CI) = 2.09-2.82) and contraindications for triptan use (OR = 2.32; 95% CI = 2.06-2.60). Continuing use vs. switching or discontinuing was most associated with current use of botulinum toxin for migraine (OR = 2.21; 95% CI = 1.42-3.44 and OR = 4.53; 95% CI = 3.14-6.55, respectively).ConclusionsAt the time of survey, CGRP-targeted mAbs remain underutilized for migraine and multiple characteristics are associated with CGRP mAb use patterns.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1468-2982
1468-2982
DOI:10.1177/03331024251341243